Selective haematological cancer eradication with preserved haematopoiesis.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
received:
07
08
2023
accepted:
23
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
22
5
2024
Statut:
aheadofprint
Résumé
Haematopoietic stem cell (HSC) transplantation (HSCT) is the only curative treatment for a broad range of haematological malignancies, but the standard of care relies on untargeted chemotherapies and limited possibilities to treat malignant cells after HSCT without affecting the transplanted healthy cells
Identifiants
pubmed: 38778101
doi: 10.1038/s41586-024-07456-3
pii: 10.1038/s41586-024-07456-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Copelan, E. A. Hematopoietic stem-cell transplantation. N. Engl. J. Med. 354, 1813–1826 (2006).
pubmed: 16641398
doi: 10.1056/NEJMra052638
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
pubmed: 29972754
pmcid: 7433347
doi: 10.1056/NEJMra1706169
Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506–519 (2017).
pubmed: 29017060
pmcid: 7025434
doi: 10.1016/j.ccell.2017.09.004
Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33, 64–74 (2019).
pubmed: 29946192
doi: 10.1038/s41375-018-0180-3
Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).
pubmed: 31501612
doi: 10.1038/s41591-019-0564-6
Becker, A. J., McCulloch, E. A. & Till, J. E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197, 452–454 (1963).
pubmed: 13970094
doi: 10.1038/197452a0
Li, Z., Czechowicz, A., Scheck, A., Rossi, D. J. & Murphy, P. M. Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation. Nat. Commun. 10, 616 (2019).
pubmed: 30728353
pmcid: 6365540
doi: 10.1038/s41467-018-08202-w
Czechowicz, A. et al. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat. Commun. 10, 617 (2019).
pubmed: 30728354
pmcid: 6365495
doi: 10.1038/s41467-018-08201-x
Russkamp, N. F., Myburgh, R., Kiefer, J. D., Neri, D. & Manz, M. G. Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Exp. Hematol. 95, 31–45 (2021).
pubmed: 33484750
doi: 10.1016/j.exphem.2021.01.003
Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789–2805 (2022).
pubmed: 35868279
doi: 10.1016/j.cell.2022.05.029
Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343–2354 (2014).
pubmed: 24596416
pmcid: 3983612
doi: 10.1182/blood-2013-09-529537
Palchaudhuri, R. et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat. Biotechnol. 34, 738–745 (2016).
pubmed: 27272386
pmcid: 5179034
doi: 10.1038/nbt.3584
Mujal, A. M. & Krummel, M. F. Immunity as a continuum of archetypes. Science 364, 28–29 (2019).
pubmed: 30948539
doi: 10.1126/science.aau8694
Borot, F. et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc. Natl Acad. Sci. USA 116, 11978–11987 (2019).
pubmed: 31138698
pmcid: 6575599
doi: 10.1073/pnas.1819992116
Humbert, O. et al. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia 33, 762–808 (2019).
pubmed: 30291334
doi: 10.1038/s41375-018-0277-8
Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439–1453 (2018).
pubmed: 29856956
pmcid: 6003425
doi: 10.1016/j.cell.2018.05.013
Kung, C. et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat. Med. 6, 343–345 (2000).
pubmed: 10700239
doi: 10.1038/73208
Kornete, M., Marone, R. & Jeker, L. T. Highly efficient and versatile plasmid-based gene editing in primary T cells. J Immunol 200, 2489–2501 (2018).
pubmed: 29445007
pmcid: 5857648
doi: 10.4049/jimmunol.1701121
Marone, R. et al. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. J. Exp. Med. https://doi.org/10.1084/jem.20231235 (2023).
Casirati, G. et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621, 404–414 (2023).
pubmed: 37648862
pmcid: 10499609
doi: 10.1038/s41586-023-06496-5
Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023).
pubmed: 37651540
pmcid: 10682510
doi: 10.1126/scitranslmed.adi1145
Chang, V. T. et al. Initiation of T cell signaling by CD45 segregation at ‘close contacts’. Nat. Immunol. 17, 574–582 (2016).
pubmed: 26998761
pmcid: 4839504
doi: 10.1038/ni.3392
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
pubmed: 32572269
doi: 10.1038/s41587-020-0561-9
Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883–891 (2020).
pubmed: 32433547
pmcid: 7357821
doi: 10.1038/s41587-020-0453-z
Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science 368, 290–296 (2020).
pubmed: 32217751
pmcid: 7297043
doi: 10.1126/science.aba8853
Kinneer, K. et al. SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads. Clin. Cancer Res. 24, 6570–6582 (2018).
pubmed: 30131388
doi: 10.1158/1078-0432.CCR-18-1300
Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790–800 (2021).
pubmed: 33989558
doi: 10.1016/S1470-2045(21)00139-X
Lazzarotto, C. R. et al. CHANGE-seq-BE enables simultaneously sensitive and unbiased in vitro profiling of base editor genome-wide activity. Preprint at biorxiv https://doi.org/10.1101/2024.03.28.586621 (2024).
Yin, H. et al. Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. Nat. Chem. Biol. 14, 311–316 (2018).
pubmed: 29377001
pmcid: 5902734
doi: 10.1038/nchembio.2559
Donohoue, P. D. et al. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells. Mol. Cell 81, 3637–3649 (2021).
pubmed: 34478654
doi: 10.1016/j.molcel.2021.07.035
Naldini, M. M. et al. Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. Nat. Commun. 14, 1285 (2023).
pubmed: 36890137
pmcid: 9995364
doi: 10.1038/s41467-023-36969-0
Dahlke, M. H., Larsen, S. R., Rasko, J. E. J. & Schlitt, H. J. The biology of CD45 and its use as a therapeutic target. Leuk. Lymphoma 45, 229–236 (2004).
pubmed: 15101706
doi: 10.1080/1042819031000151932
Webber, B. R. et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat. Commun. 10, 5222 (2019).
pubmed: 31745080
pmcid: 6864045
doi: 10.1038/s41467-019-13007-6
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
pubmed: 31634902
pmcid: 6907074
doi: 10.1038/s41586-019-1711-4
Vaxman, I. et al. Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis. Bone Marrow Transplant. 50, 706–714 (2015).
pubmed: 25665042
doi: 10.1038/bmt.2014.325
Li, Z. & Murphy, P. M. CD45: a niche marker for allotransplantation. Blood 139, 1614–1616 (2022).
pubmed: 35298604
pmcid: 8931515
doi: 10.1182/blood.2021015024
Alves, C. R. R. et al. Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01132-z (2024).
doi: 10.1038/s41551-023-01132-z
pubmed: 38057426
Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136–1147 (2021).
pubmed: 33626327
doi: 10.1016/j.stem.2021.02.002
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody–drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641–661 (2023).
pubmed: 37308581
doi: 10.1038/s41573-023-00709-2
Persaud, S. P. et al. Antibody–drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 131, https://doi.org/10.1172/JCI145501 (2021).
Saha, A. et al. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood 139, 1743–1759 (2022).
pubmed: 34986233
pmcid: 8931510
doi: 10.1182/blood.2021012366
Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220–2231 (2022).
pubmed: 36507690
doi: 10.1056/NEJMoa2206913
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
pubmed: 30135176
doi: 10.1158/2159-8290.CD-18-0442
Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
pubmed: 36109639
doi: 10.1038/s41591-022-02017-5
Lee, B. & Richards, F. M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55, 379–400 (1971).
pubmed: 5551392
doi: 10.1016/0022-2836(71)90324-X
Mitternacht, S. FreeSASA: An open source C library for solvent accessible surface area calculations. F1000Res. 5, 189 (2016).
pubmed: 26973785
pmcid: 4776673
doi: 10.12688/f1000research.7931.1
Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24–w29 (2017).
pubmed: 28472356
pmcid: 5570230
doi: 10.1093/nar/gkx346
Hopf, T. A. et al. Mutation effects predicted from sequence co-variation. Nat. Biotechnol. 35, 128–135 (2017).
pubmed: 28092658
pmcid: 5383098
doi: 10.1038/nbt.3769
Suzek, B. E. et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926–932 (2015).
pubmed: 25398609
doi: 10.1093/bioinformatics/btu739
Finn, R. D. et al. HMMER web server: 2015 update. Nucleic Acids Res. 43, W30–W38 (2015).
pubmed: 25943547
pmcid: 4489315
doi: 10.1093/nar/gkv397
Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239–250 (2018).
pubmed: 31021262
pmcid: 6694769
doi: 10.1089/crispr.2018.0014
Andrews, S. FastQC: a quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (Babraham Bioinformatics, 2010).
Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).
pubmed: 30809026
pmcid: 6533916
doi: 10.1038/s41587-019-0032-3
Lazzarotto, C. R. et al. CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity. Nat. Biotechnol. 38, 1317–1327 (2020).
pubmed: 32541958
pmcid: 7652380
doi: 10.1038/s41587-020-0555-7
Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295–302 (2021).
pubmed: 34079130
pmcid: 8266759
doi: 10.1038/s41586-021-03609-w
Chattopadhyay, G. & Varadarajan, R. Facile measurement of protein stability and folding kinetics using a nano differential scanning fluorimeter. Protein Sci. 28, 1127–1134 (2019).
pubmed: 30993730
pmcid: 6511731
doi: 10.1002/pro.3622
Gao, K., Oerlemans, R. & Groves, M. R. Theory and applications of differential scanning fluorimetry in early-stage drug discovery. Biophys. Rev. 12, 85–104 (2020).
pubmed: 32006251
pmcid: 7040159
doi: 10.1007/s12551-020-00619-2
Hong, P., Koza, S. & Bouvier, E. S. P. Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J. Liq. Chromatogr. Relat. Technol. 35, 2923–2950 (2012).
pubmed: 23378719
pmcid: 3556795
doi: 10.1080/10826076.2012.743724
Larrue, C. et al. Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia. Leukemia 37, 765–775 (2023).
pubmed: 36739349
pmcid: 10079528
doi: 10.1038/s41375-023-01835-x
Sabatier, M. et al. C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov. 13, 1720–1747 (2023).
pubmed: 37012202
doi: 10.1158/2159-8290.CD-22-0411